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Background: Gene therapy provides a novel method for the prevention and treatment of cancer, 
but the clinical application of gene therapy is restricted, mainly because of the absence of an 
efficient and safe gene delivery system. Recently, we developed a novel nonviral gene carrier, 
ie, heparin-polyethyleneimine (HPEI) nanoparticles for this purpose.
Methods and results: HPEI nanoparticles were used to deliver plasmid-expressing mouse 
survivin-T34A (ms-T34A) to treat C-26 carcinoma in vitro and in vivo. According to the in vitro 
studies, HPEI nanoparticles could efficiently transfect the pGFP report gene into C-26 cells, 
with a transfection efficiency of 30.5% ± 2%. Moreover, HPEI nanoparticle-mediated ms-T34A 
could efficiently inhibit the proliferation of C-26 cells by induction of apoptosis in vitro. Based 
on the in vivo studies, HPEI nanoparticles could transfect the Lac-Z report gene into C-26 cells 
in vivo. Intratumoral injection of HPEI nanoparticle-mediated ms-T34A significantly inhibited 
growth of subcutaneous C-26 carcinoma in vivo by induction of apoptosis and inhibition of 
angiogenesis.
Conclusion: This research suggests that HPEI nanoparticle-mediated ms-T34A may have a 
promising role in C-26 colon carcinoma therapy.
Keywords: gene therapy, mouse survivin-T34A, colon cancer, polyethyleneimine, nanoparticles, 
cancer therapy
Introduction
Manipulation of apoptosis provides new strategies for treating human disease.1 Survivin 
is one of the proteins that inhibit apoptosis and regulate cell division. Interestingly, 
survivin is prominently upregulated in most human cancers, with undetectable levels 
in normal adult tissues.2–4 These features make survivin of interest in targeted cancer 
therapy.5
Gene therapy holds promise for the treatment of various diseases for which there 
is little hope of finding a conventional cure.6 Cancer is the leading cause of death in 
economically developed countries,7 and is a major public health problem throughout 
the world. Based on GLOBOCAN 2008 estimates, about 12.7 million cancer cases 
and 7.6 million cancer deaths are estimated to have occurred in 2008. Of these, 56% 
of cases and 64% of deaths occurred in the developing world.8
Colorectal cancer is the second most common cause of cancer death in men and 
women, with an estimated incidence in the United States of 145,290 and a mortality 
rate of 56,290 in 2005.9 Worldwide, colorectal cancer affects more than one million 
people every year and is responsible for more than 0.5 million cancer-related deaths 
annually. Presently, only 70% of colorectal tumors are resectable, of which only 75% 
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are   curable. However, 25% of resected patients will have 
recurrent disease, and 19% of patients have advanced dis-
ease at the time of diagnosis, of whom the majority present 
with distal metastases, with some presenting with unresect-
able tumors.10 Survivin is highly expressed in colon cancer. 
Downregulating wild-type survivin can inhibit proliferation 
of colon cancer cells by induction of apoptosis, showing 
potential application in colon cancer therapy.11,12
Integrity of the survivin pathway is required for viability 
of cancer cells.13 Molecular antagonists of survivin including 
antisense or expression of a dominant negative mutant result 
in spontaneous apoptosis of cancer cells in vitro and in vivo. 
Survivin phosphorylation on Thr34 may be required to 
preserve cell viability at the cell division stage, and loss of 
phosphorylation on Thr34 results in apoptosis of cells.14,15 
Recent research has found that transfection of cancer cells 
with the mouse survivin Thr34 → Ala mutant (ms-T34A) 
gene led to apoptosis of cancer cells.16–18 Thus, targeting the 
survivin pathway in cancer with the ms-T34A gene is a novel 
protocol for cancer gene therapy.19,20
Currently, many cancer-associated genes are being 
identified. However, the clinical application of gene therapy 
is restricted, mainly because of the absence of effective and 
safe gene delivery technology.21–23 Polyethyleneimine (PEI) 
is one of the most efficient nonviral gene transfection agents. 
The commercially available branched   polyethyleneimine 
(25,000 kDa, PEI25K) has been used as the “gold standard” to 
evaluate the transfection efficiency of other newly developed 
nonviral gene carriers. However, polyethyleneimine is not 
biodegradable and has severe cytotoxicity.24–26 Coupling 
short PEI chains into a longer chain using biodegradable 
linkers can create biodegradable PEI derivates with high 
transfection efficiency and low toxicity, and this provides an 
interesting method for developing an advanced PEI-based 
gene carrier.27,28
Recently, we prepared biodegradable heparin-conjugated 
PEI2K (HPEI) nanoparticles as a novel nonviral gene   carrier 
with low cytotoxicity and high transfection efficiency.29 In 
this work, we used these HPEI nanoparticles to deliver the 
ms-T34A gene to treat colon cancer in vitro and in vivo. 
The results suggest that the HPEI nanoparticle-mediated 
ms-T34A gene may be a novel candidate for colon cancer 
therapy.
Materials and methods
Materials
Polyethyleneimine (molecular weight 2000, PEI2K), 
polyethyleneimine (molecular weight 25,000, PEI25K), 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), 
N-hydroxysuccinimide (NHS), 2-(N-morpholino)ethane-
sulfonic acid (MES), Dulbecco’s modified Eagle’s medium 
(DMEM), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT) were purchased from Sigma 
(St Louis, MO). Heparin (molecular weight 4000–6000) 
was purchased from Fluka (Milwaukee, WI). The C-26 
colon carcinoma cells were obtained from the American 
Type Culture Collection (Rockville, MD). Female BALB/c 
mice aged 6–8 weeks were obtained from the West China 
Experimental Animal Center. The C-26 colon carcinoma 
cells were cultured in DMEM supplemented with 10% heat-
inactivated fetal bovine serum and 100 µg/mL amikacin, and 
were maintained in a humidified chamber at 37°C in a 5% 
CO2 atmosphere.
Preparation of plasmid DNA
Plasmid pVITRO2 (Invitrogen, San Diego, CA) expressing 
ms-T34A was constructed in our laboratory.18 Escherichia 
coli colonies containing ms-T34A and a null colony were 
cultured in Luria-Bertani broth, with addition of ampicillin 
100 µg/mL. The recombinant plasmids were prepared using 
an Endofree Plasmid Giga kit (Qiagen, Chatsworth, CA). 
Endotoxin levels of the prepared plasmid DNA were deter-
mined by Tachypleus amebocyte lysate. No genomic DNA, 
small DNA fragments, or RNA were detected in the prepared 
DNA. The DNA was then dissolved in sterile endotoxin-free 
water, and the concentration of DNA was determined by 
ultraviolet spectrophotometry.
Preparation and characterization  
of HPEI nanoparticles
Preparation
HPEI was prepared according to a method previously 
described.29 Briefly, 50 mg of heparin was dissolved in MES 
solution buffer (0.05 M, 100 mL); 20 mg of EDC and 30 mg of 
NHS were then added to this solution for two hours to activate 
the carboxylic acid groups of heparin. The activated heparin 
solution was dropped into PEI2K solution (7.5 mg/mL, 20 mL) 
while stirring constantly. This reaction was carried out at room 
temperature overnight. The resulting HPEI nanoparticles were 
dialyzed in distilled water for three days, filtered by a syringe 
filter (Millex-LG, Millipore Co, Billerica, MA), adjusted to a 
concentration of 1 mg/mL, and stored at 4°C for future use.
Characterization
The morphology of the HPEI nanoparticles was observed 
under a transmission electron microscope (H-6009IV, 
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Hitachi, Japan). The HPEI nanoparticles were then diluted 
with distilled water and placed on a copper grid covered 
with nitrocellulose. Samples were negatively stained with 
phosphotungstic acid. The particle size and zeta potential of 
the HPEI nanoparticles were determined by dynamic light 
scattering (Malvern Nano-ZS 90, Worcestershire, UK). The 
temperature was kept at 25°C during the measuring process. 
All results were the mean of three test runs.
The DNA-HPEI complexes with different ratios of 
nitrogen atoms from PEI to the phosphate group from DNA 
(N/P) were electrophoresed on 1% (w/v) agarose gel for 
30 minutes at 100 V. The gel was stained with ethidium 
  bromide 0.5 mg/mL and illuminated on an ultraviolet 
illuminator to show the location of DNA.
Transfection in vitro
Twenty-four hours prior to transfection, C-26 cells were 
seeded into a six-well plate (Becton-Dickinson, Franklin 
Lakes, NJ) at a density of 1 × 105 cells per well in 2 mL of 
complete DMEM containing 10% fetal calf serum). At the 
time of transfection, the medium in each well was replaced 
with 1 mL of fresh serum-free medium. pGFP was used as a 
report gene. The amount of pGFP was kept at 2 µg/well, while 
the mass ratios of HPEI/pGFP, PEI25K/pGFP, and PEI2K/
pGFP were 5/1, 1/1, and 5/1, respectively. Six hours later, the 
medium was replaced by fresh medium. After 48 hours, the 
transfected cells were observed under a fluorescence micro-
scope (Carl Zeiss Microimaging Inc, Thornwood, NJ), and 
the transfection efficiency was recorded by flow cytometry 
(Epics Elite ESP, Beckman Coulter, Fullerton, CA).
Preparation of HPEI-DNA complexes
HPEI-DNA complexes were prepared by mixing 5 µg HPEI 
(5 µL, 1 mg/mL) solution with 1 µg of pVITRO2/GFP 
plasmid, pVITRO2/null plasmid, or pVITRO2/ms-T34A 
plasmid, followed by incubation for 30 minutes at room 
temperature.
In vitro studies
Cytotoxicity assay
C-26 cells were plated at a density of 1 × 104 cells/well into a 
96-well plate and incubated at 37°C overnight in DMEM. The 
medium was then removed, and the cells were then washed with 
serum-free DMEM without antibiotics, and 200 µL serum-free 
DMEM without antibiotics was added to the wells. Normal 
saline (control), HPEI (1 µg), the null HPEI complex (DNA-
HPEI, 0.2 µg:1 µg), or ms-T34A-HPEI   complex (DNA:HPEI, 
0.2 µg:1 µg) was then added to the wells. The plate was 
incubated for 48 hours at 37°C. Cell viability was then exam-
ined using the MTT method.
Morphological analysis
After transfection for 48 hours, C-26 cells were suspended 
in hypotonic propidium iodide solution containing 50 µg 
  propidium iodide/mL in 0.1% sodium citrate plus 0.1% 
Triton X-100, incubated in the dark for 10 minutes, and 
examined by fluorescence microscopy.
Flow cytometric analysis
After the transfected DNA (ms-T34A or null)-HPEI 
complexes (DNA:HPEI, 1:5) were incubated for 48 hours, 
the C-26 cells in the six-well plates were washed once with 
300 µL of phosphate-buffered solution, detached with 300 µL 
of trypsin/EDTA, centrifuged (1500 rpm, three minutes), and 
the supernatant was discarded. The C-26 cells were fixed 
with 75% alcohol, centrifuged (1500 rpm, three minutes), 
and resuspended with propidium iodide in an ice bath. Thirty 
minutes later, these samples were analyzed using a flow 
cytometer (ESP Elite).
In vivo study
Ten mice were subcutaneously injected with 100 µL of 
C-26 cell suspension (1 × 106) into the right flank. The 
β-galactosidase-expressing plasmid pCMV-LacZ was used 
to evaluate the transfection efficiency of HPEI in vivo. 
When the mean tumor diameter was 10 mm, the tumor-
bearing mice were randomly divided into two groups, 
and treated with intratumoral injection of null-HPEI 
(5 µg:40 µg) or Lac-Z-HPEI (5 µg:40 µg), respectively. 
After 48 hours, an in situ β-galactosidase staining kit 
(Beyotime, China) was used to detect tumor expression 
of the Lac-Z gene.
Therapy studies
Female BALB/c mice were injected subcutaneously with 
100 µL of C-26 cell suspension (1 × 106) into the right flank. 
After the tumor mean diameter reached about 6 mm, the 
tumor-bearing mice were randomly divided into four groups 
and received the following treatment by intratumoral injection: 
normal saline, HPEI nanoparticles (25 µg), null-HPEI 
complexes (5µg plasmid/ 25µg HPEI), and ms-T34A-HPEI 
complexes (5µg ms-T34A/ 25µg HPEI. The mice were treated 
with five doses at intervals of 3 days. The tumor volume was 
calculated as 0.52 × length × width2, and was recorded every 
3 days. When mice in the control group became very weak, 
they were sacrificed by dislocation of the cervical vertebra.
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Analysis of histology and apoptosis
The tumors were fixed in 4% paraformaldehyde in phosphate-
buffered solution for at least 24 hours. Tissues were embedded 
in paraffin, and at least four cross-sections 3–5 µm thick were 
taken from each tumor and stained with hematoxylin and 
eosin. A commercially available TUNEL kit (Promega, 
Madison, WI) was used to investigate the apoptotic cells in 
the C-26 tumors. This analysis was performed following the 
manufacturer’s protocol, and the samples were examined 
with a fluorescence microscope (400×).
The tumors were stored at −80°C, and to examine 
microvessel density, were immunostained with an epithelial 
cell marker goat antimouse CD31 antibody (dilution 1:100; 
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at 
4°C. Rabbit-antigoat TRITC (dilution 1:100; Santa Cruz 
Biotechnology) was added, and the tumors were then left in a 
humidified chamber protected from light at 37°C for one hour 
and counterstained with Hoechst 33258 for 10 minutes. The 
microvessel density was determined as the average number 
of CD31-positive small vessels in a field (400×).
Statistical analysis
The data were evaluated using a two-tailed unpaired   Student’s 
test or compared by one-way analysis of variance, and are 
expressed as the mean ± standard deviation. P , 0.05 was 
considered to be statistically significant.
Results and discussion
Use of advanced gene carrier systems is very important 
for developing a successful gene therapy protocol. Some 
functional genes associated with disease have been discovered, 
but the clinical use of gene therapy remains restricted, 
mainly due to the absence of safe and efficient gene delivery 
technologies. Nanoparticles have attracted attention as 
drug delivery systems.30–32 Some nanoparticle-encapsulated 
drugs are already in clinical trials or marketed.33 Cationic 
nanoparticles can be used as a nonviral gene vector in vitro 
and in vivo.34–36 PEI is one of the most efficient nonviral 
gene transfection agents. However, PEI is not biodegradable 
and has high cytotoxicity, which greatly restricts its clinical 
application.37–41 Binding short PEI chains into longer ones 
using biodegradable linkers can create PEI derivates with 
high transfection efficiency and low toxicity.42–44 These 
PEI derivates have more potential in gene therapy than the 
commercially available PEI25K.45–47 Recently, we used heparin 
to conjugate low molecular weight PEI (PEI2K), creating novel 
cationic HPEI nanoparticles with low cytotoxicity and high 
transfection efficiency.29 Up until now, HPEI nanoparticles 
have been used to deliver therapeutic genes (such as pVSVMP, 
pIL-15, and FILIP1L) to treat cancer. The results have shown 
HPEI nanoparticles to be a novel nonviral gene carrier with 
promising application in cancer gene therapy.29,48 In this 
work, we prepared a plasmid-expressing ms-T34A gene and 
used HPEI nanoparticles to deliver this gene to treat colon 
cancer in vitro and in vivo. The anticancer effect of HPEI 
nanoparticle-mediated ms-T34A gene therapy was evaluated, 
and the relevant anticancer mechanisms are discussed.
Preparation and characterization  
of HPEI nanoparticles
HPEI nanoparticles were prepared in accordance with 
our previous description, as schematically represented in 
Figure 1A. The freshly prepared HPEI nanoparticles were 
characterized in detail, and found to have a dynamic diameter 
of 78 nm ± 3.4 nm and a polydispersity index of 0.153, as 
determined by dynamic light scattering. The transmission 
electron microscopic image of the HPEI nanoparticles 
 ( Figure 1B) indicates that these particles had a mean size 
of about 26 nm. To our knowledge, transmission electron 
microscopy determines the size of dry particles, while 
dynamic light scattering determines the hydrodynamic 
diameter of particles in water. HPEI nanogels are likely to 
have high water absorption, because dry HPEI nanoparticles 
(about 26 nm) can absorb water and swell to become nano-
gels with a size of about 78 nm. Thus, there is disagreement 
about particle size measurement by dynamic light scattering 
and transmission electron microscopy. The zeta potential 
spectrum for the HPEI nanogels is presented in Figure 1C; 
these nanoparticles were cationic and had a zeta potential 
of 29 ± 0.68 mV .
The DNA-binding ability of the HPEI nanoparticles was 
evaluated by gel retardation assay, and is shown in Figure 1D. 
When the N/P was 8, complete retardation of DNA was 
achieved. This suggests that the HPEI nanoparticles could 
bind DNA completely when the N/P was $8.
The transfection efficiency of these HPEI nanoparticles 
was evaluated in C-26 cells, with GFP plasmid used as the 
report gene. We observed that many cells had GFP-derived 
green fluorescence, indicating that HPEI nanoparticles could 
efficiently transfect the gene into C-26 cells (Figure 1E). 
Moreover, flow cytometry was used to determine the trans-
fection efficiency of the HPEI nanoparticles. As shown in 
Figure 1F, HPEI nanoparticles had a transfection efficiency 
of 30.5% ± 2%, which was comparable with that of PEI25K 
(32% ± 2.5%), while the transfection efficiency of PEI2K 
was very low.
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Anticancer effect in vitro
The antitumor activity of the HPEI nanoparticle-mediated 
ms-T34A gene in the C-26 cell line was evaluated in vitro. 
After transfection with the ms-T34A-HPEI complexes for 
48 hours, viability of the C-26 cells was determined by the 
MTT method, and the results are presented in Figure 2A. 
The HPEI-mediated ms-T34A gene efficiently inhibited the 
viability of transfected C-26 cells, while HPEI nanoparticles 
and the HPEI nanoparticle-mediated null plasmid did not 
significantly reduce cell viability. This result implies that 
HPEI nanoparticle-mediated ms-T34A-HPEI has anticancer 
activity in C-26 colon cancer cells.
Moreover, we used morphological observations of 
apoptosis and flow cytometry analysis to evaluate whether 
induction of apoptosis was one of the reasons why ms-T34A-
HPEI complexes are able to kill cancer cells. The results of 
the flow cytometry are presented in Figure 2B, showing that 
ms-T34A-HPEI significantly increased the proportion of 
apoptotic cells (46.8%) compared with other agents (normal 
saline 7.5%, HPEI 9.5%, null-HPEI 18.2%). According to 
the morphological observations, there were more apoptosis 
cells (shown with arrow) in the ms-T34A-HPEI treatment 
group than in the other treatment groups (Figure 2C). 
These results suggest that induction of apoptosis was involved 
in the anticancer mechanism of HPEI nanoparticle-mediated 
ms-T34A gene therapy.
Antitumor effect of ms-T34A-HPEI  
in vivo
First, we examined the ability of HPEI nanoparticles to 
transfect the ms-T34A gene into C-26 carcinoma cells in vivo. 
Lac-Z gene was used as the report gene. The HPEI-mediated 
Lac-Z gene was intratumorally injected into the C-26 tumor 
at a volume of about 500 mm3. Forty-eight hours later, an in 
situ β-galactosidase staining kit was used to detect expression 
of β-galactosidase in vivo. As shown in   Figure 3A, the blue 
stain indicates expression of β-galactosidase, revealing that 
the Lac-Z gene could be efficiently transfected into C-26 cells 
in vivo. This result confirmed the transfection ability of HPEI 
nanoparticles in vivo.
A subcutaneous mouse colon cancer model was used 
to study the effect of ms-T34A-HPEI on tumor growth 
inhibition. Tumor-bearing mice were divided into four 
groups and treated with normal saline, HPEI, null-HPEI, or 
ms-T34A-HPEI by intratumoral injection. The tumor volume 
was recorded every three days. Four days after the final dose, 
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the mice were sacrificed, and their tumors were excised and 
preserved. The ms-T34A-HPEI treatment resulted in regres-
sion of tumor growth by 74.8%, 71.2%, and 66.2% com-
pared with the normal saline, HPEI, and null-HPEI groups, 
respectively (P , 0.05, Figure 3B). Moreover, according to 
our previous study, intratumoral injection of low-dose naked 
ms-T34A plasmid did not significantly inhibit the growth of 
C-26 carcinoma in vivo, which may be due to the limited 
expression of naked plasmid in vivo. These results suggest 
that the HPEI nanoparticle-mediated ms-T34A gene can 
inhibit growth of C-26 carcinoma in vivo.
To study the mechanism of anticancer activity for HPEI 
nanoparticle-mediated ms-T34A in vivo, we carried out 
hematoxylin and eosin staining and TUNEL assays. As shown 
in Figure 4A, many strongly positive nuclei identified as 
being in apoptotic cells could be observed in the ms-T34A-
HPEI complex-treated tumor tissues, whereas such nuclei 
were rare in the other groups by TUNEL assay. As shown in 
Figure 4B, a large number of cells with nuclear condensation 
were identified as being apoptotic in the tumor tissues treated 
with ms-T34A-HPEI complexes, whereas nuclear condensa-
tion was rare in the other groups on hematoxylin and eosin 
staining. These results imply that induction of apoptosis may 
be a mechanism for inhibition of colon cancer by ms-T34A-
HPEI complexes in vivo.
Moreover, tumor sections from each treatment group 
were stained with CD31 to evaluate microvessel   density 
and counterstained with Hoechst 33258 to mark the 
cell nucleus. Treatment with ms-T34A-HPEI resulted 
in dramatic inhibition of angiogenesis in the tumors 
(Figure 5). This implies that antiangiogenesis may be another 
mechanism for inhibition of colon cancer by the ms-T34A-
HPEI   complexes in vivo.
Survivin warrants attention as a method for targeted 
cancer therapy because of its differential expression in tumors 
versus normal tissues and as a bifunctional protein that acts 
as a suppressor of apoptosis and plays a central role in cell 
division.4,16–18 The results of propidium iodide staining and 
flow cytometric analysis in vitro as well as TUNEL staining 
in vivo suggested that ms-T34A-HPEI significantly induced 
apoptosis of cells, more so in the treated group than in 
controls. Previously, some reports also found that the survivin 
gene could kill cancer cells by inducing apoptosis,2,4,16–18 
which supports our results.
The results of CD31staining in each group indicated that 
microvessel density in the ms-T34A-HPEI group decreased 
markedly compared with controls. The generation of 
new blood vessels (angiogenesis) is important for normal 
embryonic development and for the development of patho-
logic conditions such as cancer.49 Previous studies have 
found that the ms-T34A gene can suppress tumor growth 
by inhibiting angiogenesis. This may involve upregulated 
survivin expression during the proliferative phase, with the 
nonproliferative phase of angiogenesis being a transcriptional 
target for vascular endothelial growth factors,11,50 indicating 
that vascular endothelial growth factor protects endothelial 
cells against apoptosis during angiogenesis by upregulating 
survivin.12–15 Therefore, in addition to inhibiting tumor cell 
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Figure 2 Antitumor activity of ms-T34A-HPEI on C-26 cancer cells in vitro. (A) Cell viability was measured by MTT, (B) cellular apoptosis was testified by flow cytometric 
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growth, targeted survivin may also prove to be beneficial in 
inducing apoptosis in proliferating endothelial cells within 
the tumor vasculature.17,18
Worldwide, colorectal cancer is responsible for more 
than 0.5 million cancer-related deaths annually, so new 
  therapeutics for colon cancer are needed.51,52 Gene therapy 
provides a novel method for cancer treatment. Recently, 
some gene therapy protocols for colon cancer have been 
successfully developed, and their positive results are 
encouraging.53,54 Survivin is upregulated in colon cancer 
but undetectable in normal adult tissue. Previous work has 
indicated that the ms-T34A gene can selectively kill tumor 
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Figure 3 Antitumor effect of ms-T34A-HPEI on subcutaneous C-26 tumor models in vivo. (A) Transfection ability of HPEI was evaluated in vivo, while Lac-Z gene was used as 
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cells, but not normal cells in vitro and in vivo,55,56 suggesting 
a potential therapeutic application for the ms-T34A gene in 
colon cancer.57 In this work, we used a novel nonviral gene 
carrier to deliver the ms-T34A gene, and found that ms-T34A/
HPEI complexes can inhibit tumor growth efficiently in vitro 
and in vivo. Moreover, ms-T34A/HPEI complexes did not 
show strong toxicity to normal cells and tissues. Our results 
suggest that the HPEI nanoparticle-mediated ms-T34A gene 
may be an interesting biodrug for colon cancer therapy.
Overall, HPEI nanoparticles can efficiently transfect 
this gene into C-26 colon cancer in vitro and in vivo. HPEI 
nanoparticle-mediated ms-T34A can prevent proliferation 
of C-26 cancer cells by induction of apoptosis. Moreover, 
HPEI nanoparticle-mediated ms-T34A delivery can inhibit 
growth of C-26 cancer cells in vivo by induction of   apoptosis 
and antiangiogenesis. These results suggest that HPEI 
nanoparticle-mediated ms-T34A may be a good candidate 
for colon cancer therapy.
Conclusion
HPEI nanoparticles are a novel nonviral gene carrier, and 
can efficiently transfect the ms-T34A gene into C-26 colon 
cancer cells. HPEI nanoparticle-mediated ms-T34A gene 
delivery can inhibit growth of C-26 colon cancer cells in 
vitro and in vivo. Moreover, antiangiogenesis and induction 
of apoptosis in cancer cells are involved in the anticancer 
mechanism of HPEI nanoparticle-mediated ms-T34A gene 
therapy in C-26 colon cancer. Our findings may provide some 
evidence for targeting survivin in C-26 colon cancer and 
  suggest that ms-T34A-HPEI complexes can be considered as 
a novel treatment approach for C-26 colon cancer.
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